Patents Examined by Jeffrey S. Lundgren
  • Patent number: 11993600
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: May 28, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph D. Panarese, Samuel Bartlett, Yat Sun Or
  • Patent number: 11986455
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: May 21, 2024
    Assignee: AXSOME MALTA LTD.
    Inventor: Katayoun Zomorodi
  • Patent number: 11987543
    Abstract: An 8-(4-bromobenzylideneamino)naphthalene-1,3-disulfonic acid compound, its synthesis, and its use as an antioxidant agent.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11986454
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: June 22, 2023
    Date of Patent: May 21, 2024
    Assignee: AXSOME MALTA LTD.
    Inventor: Katayoun Zomorodi
  • Patent number: 11981683
    Abstract: Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: March 19, 2022
    Date of Patent: May 14, 2024
    Assignee: Arvinas Operations, Inc.
    Inventors: Erika Marina Vieira Araujo, Michael Berlin, Hanqing Dong, Steven M. Sparks, Jing Wang, Wei Zhang
  • Patent number: 11976069
    Abstract: The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 7, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Wensheng Yu, Joseph A. Kozlowski, Dane James Clausen, Jian Liu, James Fells
  • Patent number: 11974972
    Abstract: The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: May 7, 2024
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Joong Ho Moon, Michelle Miranda
  • Patent number: 11975009
    Abstract: The present disclosure provides for a method of inhibiting the growth of a microorganism including contacting the microorganism with zinc porphyrin (ZnPor). The present disclosure also provides for a method of treating or preventing biofilm formation of one or more microorganisms including contacting the biofilm with zinc porphyrin (ZnPor). Further, the present disclosure provides for a method of treating a disease associated with biofilm formation in a subject including administering to the subject a composition comprising a therapeutically effective amount of ZnPor.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: May 7, 2024
    Assignee: ZNABLE LLC
    Inventor: Jayne Robinson
  • Patent number: 11969404
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: April 30, 2024
    Assignee: AXSOME MALTA LTD.
    Inventor: Katayoun Zomorodi
  • Patent number: 11964987
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 23, 2024
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Achyutharao Sidduri
  • Patent number: 11958835
    Abstract: A 6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(4-chlorophenyl)-2-alkoxynicotinonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 9, 2023
    Date of Patent: April 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11957752
    Abstract: The present invention relates to the technical field of photosensitizers, and particularly to a near-infrared nano-photosensitizer and a preparation method and use thereof. The near-infrared nano-photosensitizer in the present invention is modified by conjugation extension of the boron dipyrromethene core, achieving absorption and emission spectra close to the near-infrared region. A polyfluoroalkyl group and a polyethylene glycol group are introduced to the boron dipyrromethene structure to obtain an amphiphilic photosensitizer. By means of the strong fluorine-fluorine interaction between the polyfluoroalkyl group and the hydrophilic interaction of the polyethylene glycol group, a nano-photosensitive micelle with an ultra-low CMC value is ultimately constructed. Boron dipyrromethene is induced by fluorine-fluorine interaction to undergo J-aggregation, causing the maximum absorption peak to red-shift to the near-infrared region, beneficial to the deep phototherapy of tumors.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: April 16, 2024
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Zhengqing Guo, Hui He, Mengke Shi, Han Xu, Dandan Ji, Yangyang Huang, Qiujin He
  • Patent number: 11951088
    Abstract: Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 9, 2024
    Assignee: EPITRACKER, INC.
    Inventors: Stephanie Venn-Watson, John Reiner, Richard Lumpkin
  • Patent number: 11951085
    Abstract: The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: April 9, 2024
    Assignee: REMEDY PHARMACEUTICALS, INC.
    Inventor: Sven Martin Jacobson
  • Patent number: 11951091
    Abstract: Disclosed herein is a complex, a contrast agent and the method for treating a disease related to CXCR4 receptor. The complex is configured to bind the CXCR4 receptor, and is used as a medicament for diagnosis and treatment of cancers and other indications related to the CXCR4 receptor.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: April 9, 2024
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.C
    Inventors: Chien-Chung Hsia, Chung-Hsin Yeh, Cheng-Liang Peng, Chun-Tang Chen
  • Patent number: 11952382
    Abstract: An 2-benzo-[3,4-b]quinolino-[b,g]indeno[1?,2?:3,4]fluoreno-[1,2-d]oxonine-24-flouro-5,11,16,21-tetraone compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 7, 2023
    Date of Patent: April 9, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11944631
    Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: April 2, 2024
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L Kutok, Howard M. Stern
  • Patent number: 11944629
    Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 2, 2024
    Assignee: MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARARATE MBH
    Inventor: Heiner Will
  • Patent number: 11945798
    Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: April 2, 2024
    Assignees: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Hyunjoo Lee, Su Bin Choi, Young Ae Yoon, Kwan Hoon Hyun, Jae Young Sim, Marian C. Bryan, Scott Kuduk, James Campbell Robertson, Jaekyoo Lee, Paresh Devidas Salgaonkar, Byung-Chul Suh, Jong Sung Koh, So Young Hwang
  • Patent number: 11944607
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: April 2, 2024
    Assignee: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans